Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy.
Lundbeck
CPH: LUN ~$5B MCAP
Lundbeck is a Danish specialty pharmaceutical company focused on central nervous system (CNS) disorders including depression, schizophrenia, Parkinson's disease, and migraine. Vyepti (eptinezumab), its CGRP-targeting migraine therapy, is a key growth asset.
Company Info
Recent News
Lundbeck hit with untitled letter over Vyepti efficacy claims
Lundbeck hit with untitled letter over Vyepti efficacy claims (Fierce Pharma.)
Leadership Team
Careers & Job Openings